Advertisement

Topics

Bristol-Myers Squibb Company and Seattle Genetics, Inc. Company Profile

12:43 EDT 20th April 2018 | BioPortfolio

In 2011, through a collaboration agreement with Ono Pharmaceutical Co., Ltd (Ono), Bristol-Myers Squibb expanded its territorial rights to develop and commercialize Opdivo globally except in Japan, South Korea and Taiwan, where Ono had retained all rights to the compound at the time. On July 23, 2014, Bristol-Myers Squibb and Ono further expanded the companies’ strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies – as single agents and combination regimens – for patients with cancer in Japan, South Korea and Taiwan.


News Articles [1280 Associated News Articles listed on BioPortfolio]

Seattle Genetics and Bristol-Myers Squibb Highlight Interim Results from Phase 1/2 Study in Hodgkin Lymphoma

ATLANTA–(BUSINESS WIRE)–Seattle Genetics, Inc. (NASDAQ:SGEN) and Bristol-Myers Squibb Company (NYSE:BMY) today highlighted updated interim results from an ongoing phase 1/2 clinical tri...

Bristol-Myers Squibb And Nektar To Collaborate On Immuno-Oncology Program

NewsUnder the collaboration, Bristol-Myers Squibb will pay Nektar Therapeutics $1.85 billion upfront. The companies will jointly develop and commercialize NKTR-214 in combination with Bristol-Myers Sq...

Weekly Analysts' Ratings Updates for Bristol-Myers Squibb

Several brokerages have updated their recommendations and price targets on shares of Bristol-Myers Squibb in the last few weeks: 2/16/2018 - Bristol-Myers Squibb was given a new $78.00 price target on...

Bristol-Myers Squibb to Take Part in Barclays Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE: BMY) will present at Barclays Global Healthcare Conference on Wednesday, March 14, 2018, in Miami. Murdo Gordon, executive vice presiden...

Pomerantz LLP: SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bristol-Myers Squibb Company of Class Action Lawsuit and Upcoming Deadline - BMY

NEW YORK, NY / ACCESSWIRE / March 3, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company") (NYSE: BMY) an...

Brokers Offer Predictions for Bristol-Myers Squibb Co's Q3 2018 Earnings

Bristol-Myers Squibb Co - Investment analysts at William Blair dropped their Q3 2018 EPS estimates for Bristol-Myers Squibb in a report released on Wednesday. William Blair analyst M. Phipps now expec...

Bristol-Myers Squibb to Take Part in Cowen and Company 38th Annual Global Health Care Conference

Bristol-Myers Squibb Company (NYSE:BMY) will participate in the Cowen and Company 38th Annual Global Health Care Conference on Monday, March 12, 2018, in Boston. ...

Bristol-Myers Squibb to Take Part at the Citi 2017 Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Citi 2017 Global Healthcare Conference on Wednesday, December 6, 2017, in New York. Murdo Gordon, chief commer...

PubMed Articles [674 Associated PubMed Articles listed on BioPortfolio]

Treatment of Ipilimumab-Induced Vogt-Koyanagi-Harada Syndrome With Oral Dexamethasone.

The author presents a retrospective case report of a 54-year-old male with ipilimumab (Yervoy; Bristol-Myers Squibb, New York City, NY)-induced Vogt-Koyanagi-Harada Disease (VKH), which consisted of u...

THE EFFECT OF TOTAL AND PARTIAL NEPHRECTOMY ON THE PHARMACOKINETICS OF INTRAVENOUS PARACETAMOL IN HUMANS.

Paracetamol is one of the most common analgesic and antipyretic drugs. Recently intravenous paracetamol has been widely used to treat moderate postoperative pain. Surgery is the main method of treatme...

4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy.

Indoleamine 2,3-dioxygenase is a heme-containing enzyme implicated in the down regulation of the anti-tumor immune response, and considered a promising anti-cancer drug target. Several pharmaceutical ...

In Reply to Wang and Myers.

Review of "Social Media as a Platform for Surgical Learning" by Myers CG, Kudsi OY, Ghaferi AA in Ann Surg 267: 233-235, 2018.

Clinical Trials [471 Associated Clinical Trials listed on BioPortfolio]

Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects

- Objective: - A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Co...

Bioequivalence Study of Cefprozil Tablets, USP 500 mg Undef Fed Conditions

The objective of this study is to assess the single - dose relative bioavailability of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg cefprozil tablets, under fed conditions.

Bioequivalence Study of Daclatasvir From Prodactariv 60 mg Film Coated Tablets (International Drug Agency for Pharmaceutical Industry (IDI), Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Prodactariv 60 mg F.C.T (International Drug Agency for Pha...

Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Daktavira 60 mg film coated tablets ( European Egyptian Ph...

Pravastatin 80 mg Tablets Dosed in Healthy Subjects Under Non-Fasting Conditions

This study compared the relative bioavailability (rate and extent of absorption) of Pravastatin Sodium Tablets 80 mg by Teva Pharmaceutical Industries, Ltd. with that of Pravachol® Tablet...

Companies [1754 Associated Companies listed on BioPortfolio]

Bristol-Myers Squibb Company and Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize Eliquis, an oral anticoagulant discovered by Bristol-Myers Squibb. Thi...

Bristol-Myers Squibb Company & Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize ELIQUIS, an investigational oral anticoagulant discovered by Bristol-M...

Exelixis, Inc. and Bristol-Myers Squibb Company

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases....

Incyte Corporation and Bristol-Myers Squibb Company

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases....

Bristol-Myers Squibb and Pfizer

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

More Information about "Bristol-Myers Squibb Company and Seattle Genetics, Inc." on BioPortfolio

We have published hundreds of Bristol-Myers Squibb Company and Seattle Genetics, Inc. news stories on BioPortfolio along with dozens of Bristol-Myers Squibb Company and Seattle Genetics, Inc. Clinical Trials and PubMed Articles about Bristol-Myers Squibb Company and Seattle Genetics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Bristol-Myers Squibb Company and Seattle Genetics, Inc. Companies in our database. You can also find out about relevant Bristol-Myers Squibb Company and Seattle Genetics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...


Corporate Database Quicklinks



Searches Linking to this Company Record